Blacksburg, Virginia-based Keraderm Corp., an early stage medical device company that has developed a patented, innovative, and effective treatment for nail infections, completed a $2.5m Series A investment led by NewVa Capital Partners, LP.
Commenting on the round, Bill Cumbie, President and CEO of Keraderm, said: “This commitment by NewVa Capital Partners provides us with the capital and resources we need to complete our clinical trial, obtain approval for our device from the Food and Drug Administration and begin rolling out our product”.
The company is currently preparing for a pivotal trial designed to meet the requirements for approval from the U.S. Food and Drug Administration.
NewVa Capital Partners is a private equity and venture capital fund managed by Third Security, LLC and provides early stage investments in companies located or considering location in southwest Virginia.
Keraderm represents the final investment by NewVa Capital Partners, LP, which is invested in four other companies in the biotech, life sciences, and technology sectors.